Emerging therapeutic options for the treatment of patients with symptomatic asthma

Annals of Allergy, Asthma and Immunology

Volumn 115, Issue 4, 2015, Pages 265-271.e5

  McIvor, R Andrew ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BENRALIZUMAB; BRODALUMAB; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; DUPILUMAB; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; LEBRIKIZUMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; OC 000459; OXITROPIUM BROMIDE; PLACEBO; RESLIZUMAB; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UNCLASSIFIED DRUG; (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYLINDO-1-YL)ACETIC ACID; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; INDOLEACETIC ACID DERIVATIVE; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; QUINOLINE DERIVATIVE;

ADD ON THERAPY; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER INHALER; EVENING DOSAGE; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; MORNING DOSAGE; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SOFT MIST INHALER; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; INDOLEACETIC ACIDS; INTERLEUKINS; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE 4 INHIBITORS; QUINOLINES; TIOTROPIUM BROMIDE;

EID: 84944165623     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2015.07.011     Document Type: Review

References (111)

1. M. Masoli, D. Fabian, S. Holt, and R. Beasley Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report Allergy 59 2004 469 478
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/local/uploads/files/GINA-Report-2015.pdf. Last updated April 2015. Accessed July 17, 2015.
3. E.D. Bateman, H.A. Boushey, J. Bousquet, and et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med 170 2004 836 844
4. M.R. Partridge, R.W. Dal Negro, and D. Olivieri Understanding patients with asthma and COPD: insights from a European study Prim Care Respir J 20 2011 315 323
5. P. Demoly, P. Paggiaro, V. Plaza, and et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK Eur Respir Rev 18 2009 105 112
6. P. Demoly, K. Annunziata, E. Gubba, and L. Adamek Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years Eur Respir Rev 21 2012 66 74
7. R.H. Stanford, A.W. Gilsenan, R. Ziemiecki, X. Zhou, W.R. Lincourt, and H. Ortega Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS) J Asthma 47 2010 257 262
8. D. Price, M. Fletcher, and T. van der Molen Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey NPJ Prim Care Respir Med 24 2014 14009
9. T. Vos, A.D. Flaxman, M. Naghavi, and et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2163 2196
10. L.J. Akinbami, J.E. Moorman, and X. Liu Asthma prevalence, health care use, and mortality: United States, 2005-2009 Natl Health Stat Report 32 2011 1 14
11. J.I. Ivanova, R. Bergman, H.G. Birnbaum, G.L. Colice, R.A. Silverman, and K. McLaurin Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma J Allergy Clin Immunol 129 2012 1229 1235
12. R.H. Dougherty, and J.V. Fahy Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype Clin Exp Allergy 39 2009 193 202
13. M. Sadatsafavi, R. Rousseau, W. Chen, and et al. The preventable burden of productivity loss due to suboptimal asthma control: a population-based study Chest 145 2014 787 793
14. D.R. Taylor, E.D. Bateman, L.P. Boulet, and et al. A new perspective on concepts of asthma severity and control Eur Respir J 32 2008 545 554
15. M. Castro, S. Mathur, F. Hargreave, and et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study Am J Respir Crit Care Med 184 2011 1125 1132
16. S. Wenzel, L. Ford, D. Pearlman, and et al. Dupilumab in persistent asthma with elevated eosinophil levels N Engl J Med 368 2013 2455 2466
17. M. Laviolette, D.L. Gossage, G. Gauvreau, and et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia J Allergy Clin Immunol 132 2013 1086 1096
18. R.M. Nowak, J.M. Parker, R.A. Silverman, and et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma Am J Emerg Med 33 2015 14 20
19. M. Castro, J. Zangrilli, M.E. Wechsler, and et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials Lancet Respir Med 3 2015 355 366
20. W.W. Busse, S. Holgate, E. Kerwin, and et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma Am J Respir Crit Care Med 188 2013 1294 1302
21. J. Corren, R.F. Lemanske Jr., N.A. Hanania, and et al. Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 1088 1098
22. M. Noonan, P. Korenblat, S. Mosesova, and et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids J Allergy Clin Immunol 132 2013 567 574
23. H. Scheerens, J.R. Arron, Y. Zheng, and et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge Clin Exp Allergy 44 2014 38 46
24. I.D. Pavord, S. Korn, P. Howarth, and et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Lancet 380 2012 651 659
25. P. Haldar, C.E. Brightling, B. Hargadon, and et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 360 2009 973 984
26. P. Haldar, C.E. Brightling, A. Singapuri, and et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis J Allergy Clin Immunol 133 2014 921 923
27. P. Nair, M.M.M. Pizzichini, M. Kjarsgaard, and et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia N Engl J Med 360 2009 985 993
28. H.G. Ortega, M.C. Liu, I.D. Pavord, and et al. Mepolizumab treatment in patients with severe eosinophilic asthma N Engl J Med 371 2014 1198 1207
29. E.H. Bel, S.E. Wenzel, P.J. Thompson, and et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma N Engl J Med 371 2014 1189 1197
30. P. Flood-Page, C. Swenson, I. Faiferman, and et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma Am J Respir Crit Care Med 176 2007 1062 1071
31. R. Pettipher, M.G. Hunter, C.M. Perkins, and et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459 Allergy 69 2014 1223 1232
32. N. Barnes, I. Pavord, A. Chuchalin, and et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma Clin Exp Allergy 42 2012 38 48
33. D. Singh, P. Cadden, M. Hunter, and et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 Eur Respir J 41 2013 46 52
34. E.D. Bateman, J.L. Izquierdo, U. Harnest, and et al. Efficacy and safety of roflumilast in the treatment of asthma Ann Allergy Asthma Immunol 96 2006 679 686
35. J. Bousquet, M. Aubier, J. Sastre, and et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma Allergy 61 2006 72 78
36. E. van Schalkwyk, K. Strydom, Z. Williams, and et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions J Allergy Clin Immunol 116 2005 292 298
37. C. Louw, Z. Williams, L. Venter, and et al. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge Respiration 74 2007 411 417
38. G.M. Gauvreau, L.P. Boulet, C. Schmid-Wirlitsch, and et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects Respir Res 12 2011 140
39. K.A. Neville, S.J. Szefler, S.M. Abdel-Rahman, and et al. Single-dose pharmacokinetics of roflumilast in children and adolescents J Clin Pharmacol 48 2008 978 985
40. R.D. Restrepo Use of inhaled anticholinergic agents in obstructive airway disease Respir Care 52 2007 833 851
41. K.E. Belmonte Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease Proc Am Thorac Soc 2 2005 297 304
42. R. Gosens, J. Zaagsma, H. Meurs, and A.J. Halayko Muscarinic receptor signaling in the pathophysiology of asthma and COPD Respir Res 7 2006 73
43. H.W. Park The role of tiotropium in the management of asthma Asia Pac Allergy 2 2012 109 114
44. M.J. Westby, M.K. Benson, and P.G. Gibson Anticholinergic agents for chronic asthma in adults Cochrane Database Syst Rev 3 2004 CD003269
45. F. Novelli, L. Malagrinò, F.L. Dente, and P. Paggiaro Efficacy of anticholinergic drugs in asthma Expert Rev Respir Med 6 2012 309 319
46. D. Price, L. Fromer, A. Kaplan, T. van der Molen, and M. Román-Rodríguez Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim Care Respir Med 24 2014 14023
47. 2-adrenergic and muscarinic receptor therapies in asthma Curr Opin Pharmacol 16 2014 148 156
48. T.T. Hansel, H. Neighbour, E.M. Erin, and et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma Chest 128 2005 1974 1979
49. L.A. Lee, A. Briggs, L.D. Edwards, S. Yang, and S. Pascoe A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma Respir Med 109 2015 63 73
50. L.A. Lee, S. Yang, E. Kerwin, R. Trivedi, L.D. Edwards, and S. Pascoe The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study Respir Med 109 2015 54 62
51. C. Vogelmeier, B. Hederer, T. Glaab, and et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD N Engl J Med 364 2011 1093 1103
52. D.P. Tashkin, B. Celli, S. Senn, and et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
53. T. Fardon, K. Haggart, D.K.C. Lee, and B.J. Lipworth A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma Respir Med 101 2007 1218 1228
54. C. Terzano, A. Petroianni, A. Ricci, L. D'Antoni, and L. Allegra Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness Eur Rev Med Pharmacol Sci 8 2004 259 264
55. B. Sposato, A. Calabrese, R. Barzan, and C. Franco Comparison of the protective effect amongst anticholinergic drugs on methacholine-induced bronchoconstriction in asthma J Asthma 45 2008 397 401
56. S.P. Peters, S.J. Kunselman, N. Icitovic, and et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma N Engl J Med 363 2010 1715 1726
57. S.P. Peters, E.R. Bleecker, S.J. Kunselman, and et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults J Allergy Clin Immunol 132 2013 1068 1074.e1
58. ® Soft Mist™ Inhaler Int J Pharm 283 2004 1 9
59. H.A.M. Kerstjens, B. Disse, W. Schröder-Babo, and et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial J Allergy Clin Immunol 128 2011 308 314
60. ® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma Respir Res 15 2014 61
61. ® 5 μg is an efficacious 24-hour bronchodilator in adults with symptomatic asthma Respir Med 109 2015 329 338
62. E.D. Bateman, O. Kornmann, P. Schmidt, A. Pivovarova, M. Engel, and L.M. Fabbri Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma J Allergy Clin Immunol 128 2011 315 322
63. H.A.M. Kerstjens, M. Engel, R. Dahl, and et al. Tiotropium in asthma poorly controlled with standard combination therapy N Engl J Med 367 2012 1198 1207
64. H.A.M. Kerstjens, T.B. Casale, E.R. Bleecker, and et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials Lancet Respir Med 3 2015 367 376
65. ® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study PLoS One 10 2015 e0124109
66. C. Vogelberg, M. Engel, P. Moroni-Zentgraf, and et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study Respir Med 108 2014 1268 1276
67. ® in children with symptomatic asthma despite inhaled corticosteroids Respir Res 16 2015 20
68. D. Price, A. Kaplan, R. Jones, and et al. Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide J Asthma Allergy 8 2015 1 13
69. J. Willson, E.D. Bateman, I. Pavord, A. Lloyd, T. Krivasi, and D. Esser Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists Appl Health Econ Health Policy 12 2014 447 459
70. M. Laviolette, D.L. Gossage, G. Gauvreau, and et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia J Allergy Clin Immunol 132 2013 1086 1096
71. R.M. Nowak, J.M. Parker, R.A. Silverman, and et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma Am J Emerg Med 33 2015 14 20
72. M. Castro, S. Mathur, F. Hargreave, and et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study Am J Respir Crit Care Med 184 2011 1125 1132
73. M. Castro, J. Zangrilli, M.E. Wechsler, and et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials Lancet Respir Med 3 2015 355 366
74. S. Wenzel, L. Ford, D. Pearlman, and et al. Dupilumab in persistent asthma with elevated eosinophil levels N Engl J Med 368 2013 2455 2466
75. W.W. Busse, S. Holgate, E. Kerwin, and et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma Am J Respir Crit Care Med 188 2013 1294 1302
76. J. Corren, R.F. Lemanske Jr., N.A. Hanania, and et al. Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 1088 1098
77. M. Noonan, P. Korenblat, S. Mosesova, and et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids J Allergy Clin Immunol 132 2013 567 574
78. H. Scheerens, J.R. Arron, Y. Zheng, and et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge Clin Exp Allergy 44 2014 38 46
79. I.D. Pavord, S. Korn, P. Howarth, and et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Lancet 380 2012 651 659
80. P. Haldar, C.E. Brightling, B. Hargadon, and et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 360 2009 973 984
81. P. Haldar, C.E. Brightling, A. Singapuri, and et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis J Allergy Clin Immunol 133 2014 921 923
82. P. Nair, M.M.M. Pizzichini, M. Kjarsgaard, and et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia N Engl J Med 360 2009 985 993
83. H.G. Ortega, M.C. Liu, I.D. Pavord, and et al. Mepolizumab treatment in patients with severe eosinophilic asthma N Engl J Med 371 2014 1198 1207
84. E.H. Bel, S.E. Wenzel, P.J. Thompson, and et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma N Engl J Med 371 2014 1189 1197
85. P. Flood-Page, C. Swenson, I. Faiferman, and et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma Am J Respir Crit Care Med 176 2007 1062 1071
86. N. Barnes, I. Pavord, A. Chuchalin, and et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma Clin Exp Allergy 42 2012 38 48
87. D. Singh, P. Cadden, M. Hunter, and et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 Eur Respir J 41 2013 46 52
88. R. Pettipher, M.G. Hunter, C.M. Perkins, and et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459 Allergy 69 2014 1223 1232
89. C. Louw, Z. Williams, L. Venter, and et al. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge Respiration 74 2007 411 417
90. E. van Schalkwyk, K. Strydom, Z. Williams, and et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions J Allergy Clin Immunol 116 2005 292 298
91. G.M. Gauvreau, L.P. Boulet, C. Schmid-Wirlitsch, and et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects Respir Res 12 2011 140
92. E.D. Bateman, J.L. Izquierdo, U. Harnest, and et al. Efficacy and safety of roflumilast in the treatment of asthma Ann Allergy Asthma Immunol 96 2006 679 686
93. J. Bousquet, M. Aubier, J. Sastre, and et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma Allergy 61 2006 72 78
94. K.A. Neville, S.J. Szefler, S.M. Abdel-Rahman, and et al. Single-dose pharmacokinetics of roflumilast in children and adolescents J Clin Pharmacol 48 2008 978 985
95. T.T. Hansel, H. Neighbour, E.M. Erin, and et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma Chest 128 2005 1974 1979
96. L.A. Lee, A. Briggs, L.D. Edwards, S. Yang, and S. Pascoe A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma Respir Med 109 2015 63 73
97. L.A. Lee, S. Yang, E. Kerwin, R. Trivedi, L.D. Edwards, and S. Pascoe The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study Respir Med 109 2015 54 62
98. T. Fardon, K. Haggart, D.K.C. Lee, and B.J. Lipworth A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma Respir Med 101 2007 1218 1228
99. C. Terzano, A. Petroianni, A. Ricci, L. D'Antoni, and L. Allegra Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness Eur Rev Med Pharmacol Sci 8 2004 259 264
100. B. Sposato, A. Calabrese, R. Barzan, and C. Franco Comparison of the protective effect amongst anticholinergic drugs on methacholine-induced bronchoconstriction in asthma J Asthma 45 2008 397 401
101. S.P. Peters, S.J. Kunselman, N. Icitovic, and et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma N Engl J Med 363 2010 1715 1726
102. S.P. Peters, E.R. Bleecker, S.J. Kunselman, and et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults J Allergy Clin Immunol 132 2013 1068 1074.e1
103. H.A.M. Kerstjens, B. Disse, W. Schröder-Babo, and et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial J Allergy Clin Immunol 128 2011 308 314
104. ® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma Respir Res 15 2014 61
105. ® 5 μg is an efficacious 24-hour bronchodilator in adults with symptomatic asthma Respir Med 109 2015 329 338
106. E.D. Bateman, O. Kornmann, P. Schmidt, A. Pivovarova, M. Engel, and L.M. Fabbri Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma J Allergy Clin Immunol 128 2011 315 322
107. H.A.M. Kerstjens, M. Engel, R. Dahl, and et al. Tiotropium in asthma poorly controlled with standard combination therapy N Engl J Med 367 2012 1198 1207
108. H.A.M. Kerstjens, T.B. Casale, E.R. Bleecker, and et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials Lancet Respir Med 3 2015 367 376
109. ® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study PLoS One 10 2015 e0124109
110. C. Vogelberg, M. Engel, P. Moroni-Zentgraf, and et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study Respir Med 108 2014 1268 1276
111. ® in children with symptomatic asthma despite inhaled corticosteroids Respir Res 16 2015 20